Research on brain aneurysms spans several active fronts, from devices that reroute blood flow away from weakened artery walls to genetic studies identifying who is most at risk. Brain aneurysms affect an estimated 1 to 6% of the general population, and a rupture carries an early mortality rate of 25 to 50%. That gap between how common aneurysms are and how deadly ruptures can be drives a wide range of scientific efforts to improve detection, prediction, and treatment.
Newer Flow Diverters for Sealing Aneurysms
One of the most active areas of device research involves flow diverters: small mesh tubes placed inside an artery to redirect blood away from the aneurysm, essentially starving it of flow until the body seals it off with a natural clot. The latest generation builds on earlier designs with surface coatings intended to reduce the risk of blood clots forming on the device itself, which has been a persistent concern with older models.
Early clinical data on one such next-generation device showed complete closure of the aneurysm in about 82% of cases at an average follow-up of roughly seven months. That study, published in Science Progress, was small (22 aneurysms in 21 patients), but it reflects a broader trend: manufacturers are iterating quickly on flow diverter design, and researchers are tracking whether each new version improves closure rates or reduces complications. Larger, longer trials are underway to see how these devices perform over years rather than months.
Liquid Embolics as an Alternative to Coiling
Traditional coiling involves threading tiny platinum coils into the aneurysm to fill the space and promote clotting. Researchers have been testing liquid embolic agents, injectable polymers that solidify inside the aneurysm, as either a replacement for or a complement to coils. One well-studied polymer is an ethylene-vinyl alcohol copolymer that hardens on contact with blood.
In experimental models, using the liquid agent alone achieved about 84% occlusion on average, with half of the aneurysms completely sealed at two-week follow-up. Combining the liquid with traditional coils pushed the complete occlusion rate to 73% at two weeks. The coils act as a scaffold, giving the liquid something to grip and fill around more completely. Despite promising results, liquid embolics haven’t become a standard option yet. Controlling where the liquid flows during injection remains technically challenging, and longer-term data in humans is still limited.
Medications That May Prevent Rupture
Not every aneurysm needs surgery. Many are small and monitored over time. This has fueled a search for medications that could stabilize aneurysm walls and reduce the chance of rupture, potentially sparing patients from invasive procedures altogether.
A large cross-sectional study published in PLOS One found that three common drug classes were associated with significantly lower odds of aneurysm rupture. Cholesterol-lowering statins were linked to a 46% reduction in rupture odds. Calcium channel blockers, a type of blood pressure medication, showed a 59% reduction. And a class of blood pressure drugs called angiotensin II receptor blockers showed a 33% reduction. Importantly, these associations held up in dose-response analyses, meaning higher doses correlated with even lower rupture risk for specific drugs within each class.
The mechanisms likely involve more than just lowering blood pressure or cholesterol. Statins, for example, have anti-inflammatory and antioxidant effects that may directly protect artery walls. One notable finding from the same study: non-aspirin anti-inflammatory painkillers were associated with a threefold increase in rupture odds, a result that warrants caution even though it doesn’t prove causation. None of these medications are approved specifically for aneurysm prevention yet, but clinical trials testing them in that role are a logical next step.
Predicting Rupture With Blood Flow Modeling
One of the hardest questions in aneurysm management is figuring out which ones will rupture. Size matters, but it’s far from the whole story. Researchers are using computational fluid dynamics, essentially computer simulations of blood flowing through a patient’s actual artery anatomy, to measure forces acting on aneurysm walls.
A key metric is wall shear stress, the drag force that flowing blood exerts on the vessel lining. Research published in the American Journal of Neuroradiology found that ruptured aneurysms had significantly more surface area exposed to abnormally low wall shear stress: 27% of the aneurysm surface in ruptured cases versus 11% in unruptured ones. In absolute terms, ruptured aneurysms had low-shear areas averaging 128 square millimeters compared to just 22 in unruptured aneurysms.
Low shear stress matters because it’s thought to weaken the vessel wall over time, promoting inflammation and degeneration at those specific spots. Interestingly, peak shear stress was similar between ruptured and unruptured aneurysms, suggesting that the area of weakness, not just the intensity of force, is what tips an aneurysm toward rupture. The goal is to eventually incorporate these measurements into clinical decision-making, giving doctors a physics-based tool alongside size and location when deciding whether to treat or monitor.
Inflammatory Markers as Warning Signs
Inflammation plays a central role in weakening aneurysm walls, and researchers are investigating whether routine blood tests could help flag dangerous aneurysms. A 2025 study evaluated several inflammatory markers in patients with ruptured aneurysms and found that white blood cell counts, neutrophil levels, C-reactive protein (a general marker of inflammation), and ratios like the neutrophil-to-lymphocyte ratio were all elevated in patients with worse outcomes.
These markers are already measured in standard blood panels, which makes them attractive as potential screening or monitoring tools. The challenge is specificity: inflammation rises in response to many conditions, so researchers need to determine whether particular patterns or thresholds are unique enough to aneurysm instability to be clinically useful on their own or in combination with imaging data.
Genetic Research and Risk Profiling
Brain aneurysms run in families. If you have two or more first-degree relatives with a history of aneurysm, your own risk is substantially higher than the general population’s. Genetic research is working to identify exactly which genes contribute to that risk, with the ultimate aim of developing targeted screening or even gene-based therapies.
A genome-wide study using a technique called Mendelian randomization identified seven gene targets reliably associated with unruptured aneurysms. These genes are involved in processes like how cells respond to low oxygen, how arteries develop, and how certain minerals are absorbed. Some of these gene targets also showed promising binding with existing drug compounds in molecular docking analyses, which is an early computational step toward repurposing known medications for aneurysm prevention. This work is still far from the clinic, but it’s narrowing the list of biological pathways that matter most.
Better Scoring Systems for Treatment Decisions
For the roughly 3 to 6 million Americans living with an unruptured aneurysm, the central question is often: do we treat it now or watch it? Two scoring systems help clinicians and patients navigate that decision.
The PHASES score estimates five-year rupture risk based on six factors: the patient’s geographic population, whether they have hypertension, their age, the aneurysm’s size, whether they’ve had a prior brain hemorrhage, and the aneurysm’s location. It’s straightforward and widely used, but it only addresses rupture risk, not whether treatment itself might be riskier than observation.
The UIATS (Unruptured Intracranial Aneurysm Treatment Score) takes a broader view, weighing rupture risk factors against treatment risk factors. It considers everything the PHASES score does plus aneurysm shape, the patient’s existing health conditions, treatment complexity, and quality-of-life factors. Research comparing the two systems in patients with multiple aneurysms suggests UIATS may be better at identifying which specific aneurysm in a patient actually ruptured, because it accounts for more variables. Ongoing work aims to refine both tools with data from flow modeling and inflammatory markers, potentially creating a single integrated risk calculator.